Tesamorelin: GHRH Analog Research Overview

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone. Labeling describes it as a 44-amino-acid GHRH(1-44) analog, structurally modified relative to native GHRH to improve stability. It acts at the GHRH receptor on pituitary somatotroph cells, and the literature describes it as stimulating endogenous growth hormone release rather than supplying growth hormone directly.

That mechanistic distinction matters in research design. A GHRH analog acts upstream, so responses depend on an intact hypothalamic-pituitary axis; exogenous growth hormone bypasses that dependency.

The core evidence base for tesamorelin comes from randomized, placebo-controlled trials in HIV-infected patients with abdominal fat accumulation. A 2010 trial reported in the Journal of Acquired Immune Deficiency Syndromes evaluated tesamorelin against placebo with a safety extension and reported reductions in visceral adipose tissue.

Follow-on analyses examined what accompanied that visceral fat reduction. A 2011 report in AIDS looked at inflammatory markers, a 2012 report in Clinical Infectious Diseases examined associated metabolic profile changes, and a 2017 report in AIDS examined liver enzymes. A 2015 PLoS One analysis looked at predictors of treatment response, and a 2011 review in Drugs summarized the compound's use in HIV-associated lipodystrophy.

Two limitations are important when reading this literature. First, the population studied is specific — HIV-associated lipodystrophy — not healthy adults or general research subjects. Second, published follow-up indicates that visceral fat effects reversed after treatment was discontinued.

Tesamorelin is FDA-approved as Egrifta and Egrifta SV for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. That approval is narrow. It does not extend to general body-composition, anti-aging, athletic, or wellness use, and no such use is approved.

Research-grade tesamorelin is not the approved product. It is supplied here as a laboratory research material only.

Supplied as lyophilized powder in a sealed vial. GHRH-family peptides are generally treated as moisture- and temperature-sensitive: keep sealed, equilibrate before opening, reconstitute with an appropriate solvent, aliquot rather than repeatedly freezing and thawing, and protect solutions from prolonged room-temperature exposure. Record the lot number with your data.

Tesamorelin lots we list are submitted for independent analysis covering identity and chromatographic purity, with results tied to the lot number on the vial. Certificates are published in the COA library and are available on request for your specific lot.

This monograph summarizes published scientific literature for educational and reference purposes only. It is not medical, veterinary, clinical, or dosing guidance, and nothing here should be read as a claim that this compound is safe, effective, or approved for use in humans or animals.

Material supplied by North Summit Labs is intended strictly for in-vitro laboratory research by qualified professionals. It is not a drug, supplement, food, cosmetic, or medical device, and it is not for human or animal consumption. Investigators are responsible for complying with their own institutional oversight, biosafety, and legal requirements.